NDA 216185 · Aucta
Motpoly Xr
Lacosamide · Oral
Last checked: Nov 20, 2026Latest source record: Jun 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 4, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
96
41 Phase 3, 6 recruiting
FAERS reports
19,419
16,935 serious, 1,904 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 16, 2025.
MOTPOLY XR is indicated for: Treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and in pediatric patients weighing at least 50 kg (1.2) 1.1 Partial-Onset Seizures MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg. 1.2 Primary Generalized Tonic-Clonic Seizures MOTPOLY XR is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and in pediatric patients weighing at least 50 kg. Additional pediatric use information is approved for UCB Inc.'s Vimpat (lacosamide) tablets, oral solution, and intravenous solution. However, due to UCB Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Mechanism: The precise mechanism by which MOTPOLY XR exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 7, 2024 Supplement 1 · Efficacy LabelMedication GuideLetter
- May 4, 2023 Original approval · Type 3 - New Dosage Form LetterLabelReview
3 products under this application
- MOTPOLY XR · LACOSAMIDE 150MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- MOTPOLY XR · LACOSAMIDE 200MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- MOTPOLY XR · LACOSAMIDE 100MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lacosamide" as an intervention, any sponsor and status, largest first.
- Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and OlderPivotal-lookingCompleted
NCT01243177 · 888 participants · Start Apr 2011 · Primary completion Jul 2015
Drug: Lacosamide; Carbamazepine-Controlled Release · For: Epilepsy; Monotherapy
Sites: Alabaster, Alabama; Huntsville, Alabama; Phoenix, Arizona · 184 sites in all
- Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.Pivotal-lookingCompleted
UCB PharmaUCB
NCT00546351 · 621 participants · Start May 2004 · Primary completion Jan 2011
Drug: Lacosamide · For: Painful Diabetic Neuropathy
Sites: Vienna, Austria; Antwerp, Belgium; Bonheiden, Belgium · 101 sites in all
- Lacosamide Versus Propranolol in MigrainePivotal-lookingCompleted
Kafrelsheikh UniversityAcademic, hospital or other
NCT05851781 · 600 participants · Start Jun 1, 2022 · Primary completion Jul 30, 2023
Drug: Lacosamide tablet; Propranolol · For: Migraine Disorders
Sites: Kafr ash Shaykh, Egypt
- Seizure Prevention in Traumatic Brain Injury With Levetiracetam and LacosamidePivotal-lookingRecruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT06866691 · 600 participants (planned) · Start Apr 18, 2025 · Primary completion Apr 2027
Drug: levetiracetam; lacosamide · For: Traumatic Brain Injury
Sites: Winston-Salem, North Carolina
- Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPivotal-lookingNot yet recruiting
University of MichiganAcademic, hospital or other
NCT07795593 · 600 participants (planned) · Start Nov 2026 · Primary completion May 2031
Drug: Oral Medication; Topical Medication · For: Painful Diabetic Neuropathy (PDN); Diabetic Nephropathies
Sites: Stanford, California; Jacksonville, Florida; Chicago, Illinois · 23 sites in all
- Lacosamide Versus Topiramate in MigrainePivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT06243692 · 600 participants (planned) · Start Feb 1, 2024 · Primary completion Feb 2, 2025
Drug: Lacosamide 50 MG; Topiramate 50Mg Tab · For: Migraine Disorders
Sites: Kafr ash Shaykh, Egypt
- Zonisamide Versus Topiramate in MigrainePivotal-lookingCompleted
Kafrelsheikh UniversityAcademic, hospital or other
NCT06347497 · 600 participants · Start Apr 1, 2024 · Primary completion Apr 1, 2026
Drug: Zonisamide 50 MG; Topiramate 50 MG · For: Migraine
Sites: Kafr ash Shaykh, Egypt
- Valproate Versus Propranolol in MigrainePivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT06485726 · 600 participants (planned) · Start Jan 23, 2023 · Primary completion Jul 1, 2024
Drug: Valproic Acid 500 MG; Propranolol · For: Migraine Disorders
Sites: Kafr ash Shaykh, Egypt
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure3,522
- drug ineffective3,033
- off label use2,359
- status epilepticus811
- dizziness741
- drug interaction736
- epilepsy720
- fall716
- somnolence701
- generalised tonic-clonic seizure674
- overdose652
- multiple-drug resistance603
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 197 |
| 2010 | 397 |
| 2011 | 496 |
| 2012 | 282 |
| 2013 | 205 |
| 2014 | 218 |
| 2015 | 267 |
| 2016 | 380 |
| 2017 | 660 |
| 2018 | 1,320 |
| 2019 | 1,379 |
| 2020 | 1,326 |
| 2021 | 1,806 |
| 2022 | 1,896 |
| 2023 | 2,023 |
| 2024 | 2,509 |
| 2025 | 2,360 |
| 2026 | 1,697 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Motpoly XR (Lacosamide)
2024 spending
$394K
Beneficiaries
106
349 claims
Per beneficiary
$3,719
$20.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $394,240 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vestibular paroxysmia: a systematic review.
Dieterich M, Brandt T · J Neurol 2025 · Systematic Review
- Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Moore A, Bidonde J, Fisher E, et al. · Rheumatology (Oxford) 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- Palliative care and end-of-life care in adults with malignant brain tumors.
Koekkoek JAF, van der Meer PB, Pace A, et al. · Neuro Oncol 2023 · Systematic Review
- Antiseizure Medications in Poststroke Seizures: A Systematic Review and Network Meta-Analysis.
Misra S, Wang S, Quinn TJ, et al. · Neurology 2025 · Systematic Review, Network Meta-Analysis
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2011 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2010 · Systematic Review
Sponsor: Aucta
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.